Literature DB >> 20083918

Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients.

Deborah J Cook1, Mark A Crowther.   

Abstract

Critically ill patients in the medical-surgical intensive care unit are at high risk for deep venous thrombosis and pulmonary embolism, which comprise venous thromboembolism. Herein, we describe the prevalence, incidence, risk factors, clinical consequences, prophylaxis against venous thromboembolism in critically ill patients, and compliance with thromboprophylaxis. We focus primarily on medical-surgical intensive care unit patients, who represent the largest subgroup of critically ill patients. Despite the large and growing number of critically ill patients in our aging society, their high risk for venous thromboembolism, and the morbidity and mortality associated with this complication of critical illness, relatively few rigorous studies are available. Large, well-designed, randomized trials of thromboprophylaxis, powered to detect differences in patient-important outcomes, are required to advance our understanding and care of these vulnerable patients. Furthermore, because thromboprophylaxis is a common error of omission in hospitalized patients, redoubled efforts are needed to ensure that it is used in practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20083918     DOI: 10.1097/CCM.0b013e3181c9e344

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  25 in total

1.  [Additive therapies : Intensive care studies from 2018-2019].

Authors:  M Dietrich; C J Reuß; C Beynon; A Hecker; C Jungk; D Michalski; C Nusshag; K Schmidt; M A Weigand; M Bernhard; T Brenner
Journal:  Anaesthesist       Date:  2020-01       Impact factor: 1.041

2.  ICM focus on thrombosis and bleeding.

Authors:  Morten Hylander Møller; Markus B Skrifvars; Elie Azoulay
Journal:  Intensive Care Med       Date:  2017-10-23       Impact factor: 17.440

3.  Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition.

Authors:  Sara S Cheng; Kristen Nordenholz; David Matero; Nathan Pearlman; Martin McCarter; Csaba Gajdos; Christine Hamiel; Angela Baer; Elizabeth Luzier; Zung Vu Tran; Timothy Olson; Kelly Queensland; Ryan Lutz; Paul Wischmeyer
Journal:  Intensive Care Med       Date:  2012-01-10       Impact factor: 17.440

4.  Surveillance or no surveillance ultrasonography for deep vein thrombosis and outcomes of critically ill patients: a pre-planned sub-study of the PREVENT trial.

Authors:  Yaseen M Arabi; Karen E A Burns; Sami J Alsolamy; Mohammed S Alshahrani; Fahad M Al-Hameed; Zia Arshad; Mohammed Almaani; Hassan Hawa; Yasser Mandourah; Ghaleb A Almekhlafi; Abdulsalam Al Aithan; Imran Khalid; Jalal Rifai; Gulam Rasool; Sheryl Ann I Abdukahil; Jesna Jose; Lara Y Afesh; Abdulaziz Al-Dawood
Journal:  Intensive Care Med       Date:  2020-02-24       Impact factor: 17.440

5.  Adequate thromboprophylaxis in critically ill patients.

Authors:  Marcel Levi
Journal:  Crit Care       Date:  2010-04-21       Impact factor: 9.097

6.  Incidence and acute complications of asymptomatic central venous catheter-related deep venous thrombosis in critically ill children.

Authors:  Edward Vincent S Faustino; Philip C Spinella; Simon Li; Matthew G Pinto; Petronella Stoltz; Joana Tala; Mary Elizabeth Card; Veronika Northrup; Kenneth E Baker; T Rob Goodman; Lei Chen; Cicero T Silva
Journal:  J Pediatr       Date:  2012-08-09       Impact factor: 4.406

7.  The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis.

Authors:  Shmeylan A Al Harbi; Mohammad Khedr; Hasan M Al-Dorzi; Haytham M Tlayjeh; Asgar H Rishu; Yaseen M Arabi
Journal:  BMC Pharmacol Toxicol       Date:  2013-11-11       Impact factor: 2.483

8.  A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial.

Authors:  Sian Robinson; Aleksander Zincuk; Ulla Lei Larsen; Claus Ekstrøm; Palle Toft
Journal:  Trials       Date:  2014-06-13       Impact factor: 2.279

Review 9.  Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux.

Authors:  Marcello Di Nisio; Ettore Porreca
Journal:  Drug Des Devel Ther       Date:  2013-09-16       Impact factor: 4.162

10.  Subclavian central venous catheter-related thrombosis in trauma patients: incidence, risk factors and influence of polyurethane type.

Authors:  Ariane Gentile; Laurent Petit; Françoise Masson; Vincent Cottenceau; Josseline Bertrand-Barat; Geneviève Freyburger; Catherine Pinaquy; Alain Léger; Jean-François Cochard; François Sztark
Journal:  Crit Care       Date:  2013-05-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.